Legal Disclaimer

This page provides general legal orientation for United Kingdom, not legal advice. Regulations change frequently. Always verify current rules with MHRA and consult a qualified professional.

Peptide Legal Status in United Kingdom

Moderate

The UK regulates peptides as medicines under the Human Medicines Regulations 2012. GLP-1 agonists (semaglutide, tirzepatide) are licensed and available via NHS and private prescription. Research peptides like BPC-157 lack marketing authorization and fall into a legal gray area — they are not explicitly scheduled but cannot be legally sold for human consumption without MHRA approval.

Regulator

MHRA (Medicines and Healthcare products Regulatory Agency) — Official website

Key Facts

Regulatory Stance
moderate
Compounding Allowed
Yes
Telehealth Prescribing
Yes

Compounding Pharmacy Rules

Compounding (known as 'special' or 'unlicensed' medicines in the UK) is permitted under MHRA oversight. Section 10 exemptions allow pharmacists to prepare unlicensed medicines for individual patients. GPhC-registered pharmacies and MHRA-licensed facilities may compound. FDA Category 2 does not apply in the UK, but unlicensed medicines face stricter liability rules.

Telehealth Prescribing

Online prescribing is legal in the UK when conducted by GMC-registered doctors through CQC-registered services. Asynchronous (questionnaire-based) prescribing is common for GLP-1 weight management. The GPhC requires online pharmacies to verify patient identity. The CQC inspects online prescribing services.

Peptide Categories in United Kingdom

Approved

Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro), liraglutide (Saxenda) — all licensed by MHRA and NICE-approved for NHS use in specific indications.

Research / Unapproved

BPC-157, TB-500, GHRP-2, GHRP-6, ipamorelin, CJC-1295 — no UK marketing authorization. Cannot be legally sold for human consumption. Sold as 'research chemicals' with disclaimers, but MHRA may treat as unlicensed medicines if intended for human use.

Banned / Restricted

Peptides scheduled under the Misuse of Drugs Act (e.g., certain growth hormone secretagogues if classified). AOD-9604 and fragment peptides face additional scrutiny. Check current MHRA scheduling.

Key Legislation

  • Human Medicines Regulations 2012
  • Medicines Act 1968
  • Misuse of Drugs Act 1971 (for scheduled peptides)

Peptides in United Kingdom: FAQ

Sources

Peptide Laws in Other Countries

CanadaAustraliaEuropean UnionSingaporeUnited Arab EmiratesNew ZealandGermanyNetherlandsFranceSpainHong KongJapanSouth Korea